The difference is considered that how the plasma renin activity, plasma aldosterone concentration and plasminogen activator inhibitor 1(PAI-1) are affected by different types of angiotensin receptor blockers (ARBs).Design and Method:
We performed a 24-week prospective study in 12 patients with hypertension who were receiving maintenance dialysis. For the first 12 weeks, they received valsartan 80 mg/day, which was then changed to olmesartan 20 mg/day for the second 12 weeks. We measured blood pressure, plasma renin activity, plasma aldosterone concentration, and PAI-1 as a marker of vascular endothelial damage.Results:
No significant differences in blood pressure and plasma renin activity were observed before and after the drug was changed. However, blood aldosterone concentration and PAI-1 levels declined significantly after the drug was changed.Conclusions:
This was not a crossover study, so whether these changes could have been caused by ARBs administration itself could not be determined. Still, olmesartan has been reported to have better effect in terms of increasing endogenous Ang1–7 level via ACE2 activity. This suggests that the renal-protective action as mediated by ACE2/Ang1–7/Mas receptors may differ depending on the type of ARBs, which is something that has received attention recently.